Abstract 40P
Background
Identification of tumor associated antigens (TAAs) expressed on the cell membrane of tumoral cells is a main goal in cancer research. T cell engagers (TCE) are bi-specific antibodies that engage a TAA with an effector T cell receptor mainly CD3. Kallikrein-2 (KLK2) is a surface protein for which TCE are currently in clinical development. In our study we explore genomic correlates and the transcriptomic and immunologic profile of tumors with high expression of KLK2.
Methods
Primary prostate cancer data was downloaded from TCGA to study transcripts up or down regulated when high expression of KLK2 was present. Tumor Estimation Resource (TIMER) platform was employed to investigate the association between high expression of KLK2 and immune cell populations. Correlations between transcripts were performed using Spearman’s correlation test.
Results
KLK2 was specifically upregulated in prostate cancer compared with other solid tumors and normal tissue (tumor 5956.5 TPM versus normal 4175.26 TPM). KLK2 expression did not associate with the presence of any immune cell population either innate or adaptive cells including CD8+ (Rho = 0.339, p = 1.03E-12), CD4+ (Rho = -0.244, p = 4.56E-07), B cells (Rho = 0.047, p = 0.332), neutrophils (Rho = -0.139, p =0.004), dendritic cells (Rho =-0.152, p = 0.001), or macrophages (Rho= 0.074, p =0.128). No clear association was observed for any biomarker of T cell activation including CD8A, CD8B, GZMA, GZMb or PRF1, or an additional battery including more than 40 additional genes linked with T cell cytotoxic. A mild correlation was observed between high expression of KLK2 and TMPRSS2 (Rho = 0.481, p = 1,68E-11). Protein protein interaction analysis showed interactions with AR, KLK3, IGF1, IGFBP3 (PPI enrichment p-value: 4.51e-07), among others. Co- upregulated surface proteins include TMEFF2, OR51E2, CD320 and FAM17AB; and nonsurface proteins: RDH11, FX4D3, SSR4 and NDUFA13. None of them were specifically expressed in tumoral cells or associated with biochemical (PSA) relapse.
Conclusions
KLK2 is highly and exclusively expressed in prostate cancer mainly in inmune desert tumors. Future studies should be performed in other clinical scenarios like in androgen resistant prostate tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
V. Moreno Garcia: Financial Interests, Personal, Advisory Board: BMS, Janssen, Roche, Basilea, Bayer, AstraZeneca; Financial Interests, Personal, Full or part-time Employment: START; Financial Interests, Institutional, Local PI, AbbVie, AceaBio, Adaptimmune, ADC Therapeutics, Aduro, Agenus, Amcure, Amgen, Astellas, AstraZeneca Bayer BeiGene BioInvent International AB, BMS, Boehringer Ingelheim, Boston, Celgene, Daiichi Sankyo, Debiopharm, Eisai, e-Terapeutics, Exelisis, Forma Therapeutics, Genmab, GSK, Harpoon, Hutchison, Immutep, Incyte, Inovio, Iovance, Janssen, Kyowa Kirin, Lilly, Loxo, MedSir, Menarini, Merck, Merus, Millennium, MSD, Nanobiotix, Nektar, Novartis, Odonate Therapeutics, Pfizer, Pharma Mar, PharmaMar, Principia, PsiOxus, Puma, Regeneron, Rigontec, Roche, Sanofi, Sierra Oncology, Synthon, Taiho, Takeda, Tesaro, Transgene, Turning Point Therapeutics, Upshersmith: Multiple. E. Calvo: Financial Interests, Personal, Advisory Board: Adcendo, Amunix, Anaveon, AstraZeneca, BMS, Janssen, MonTa, MSD, Nanobiotix, Nouscom, Novartis, Servier, TargImmune, T-knife, Chugai, Elevation Oncology, Ellipses Pharmacy, SyneosHealth, Genmab, Diaccurate; Financial Interests, Personal, Invited Speaker: OncoDNA, PharmaMar, Roche/Genentech; Financial Interests, Personal, Full or part-time Employment, Director, Clinical Research: HM Hospitales Group; Financial Interests, Personal, Full or part-time Employment, Medical Oncologist. Clinical Investigator. Director, Clinical Research: START Madrid - CIOCC (Centro Integral Oncológico Clara Campal); Financial Interests, Personal, Member of Board of Directors, External Independent member of Board of Directors: PharmaMar; Financial Interests, Personal, Ownership Interest: START, Oncoart Associated; Financial Interests, Personal, Steering Committee Member, Member of Data Monitoring Committee: BeiGene, Sanofi, Merus; Financial Interests, Personal, Steering Committee Member: Novartis; Non-Financial Interests, Other, Non-for-profit Foundation. President and co-founder: INTHEOS (Investigational Therapeutics in Oncological Sciences) non-for-profit Foundation; Non-Financial Interests, , Advisory Role: PsiOxus; Non-Financial Interests, Other, Chair of the Independent Data Monitoring Committee: EORTC IDMC; Non-Financial Interests, Member of Board of Directors, Non-for-profit Foundation, trustee member: Non-for-profit Foundation PharmaMar; Non-Financial Interests, Advisory Role, Non-for-profit foundation: CRIS Cancer Foundation, non-for-profit ; Non-Financial Interests, Member: ASCO, ESMO, SEOM, EORTC. All other authors have declared no conflicts of interest.
Resources from the same session
89P - Cold atmospheric plasma-activated fluids as a potential new intravesical agent for the treatment of bladder cancer
Presenter: Maria Filomena Botelho
Session: Poster session 09
90P - Discovery of CMPD1 as a tumor-specific cytotoxic microtubule inhibitor
Presenter: Mamoru Takada
Session: Poster session 09
91P - Erythroid precursor-differentiated myeloid cells promote pulmonary metastasis in hepatocellular carcinoma
Presenter: Wei-hang Zhu
Session: Poster session 09
92P - Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs
Presenter: Hsing-Pang Hsieh
Session: Poster session 09
93P - Transcriptome changes of immune cells across chemotherapy of triple-negative breast cancer
Presenter: Tatiana Gerashchenko
Session: Poster session 09
509P - Spatial analysis of tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
Presenter: Markus Kleinberger
Session: Poster session 09
510P - CD47 regulates cellular and metabolic plasticity in glioblastoma
Presenter: Ruhi Polara
Session: Poster session 09
511P - Immunodisruptive conditions and glioma diagnosis: 24-year retrospective study of an under-recognized scenario
Presenter: Santiago Cabezas-Camarero
Session: Poster session 09
512P - Heterozygous germline Fanconi anemia-related gene mutations increase susceptibility to central nervous system germ cell tumors
Presenter: Guangyu Wang
Session: Poster session 09
513P - Cyclin pathway in oligodendrogliomas IDH mut and 1p/19q codeleted
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 09